Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.81 |
| ▸ | ECE1 | P42892 | 1/20 | 0.78 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.78 |
| ▸ | CCKBR | P32239 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360422 | 0.96 | GLP1R (0.88) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL29366649 | 0.94 | GLP1R (0.88) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL29462206 | 0.94 | GLP1R (0.88) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL2899791 | 0.94 | GLP1R (0.87) | GLP1R | |
| Glp-1 SCHEMBL29353361 | 0.93 | GLP1R (0.89) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL31060658 | 0.93 | GLP1R (0.89) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL30683162 | 0.92 | GLP1R (0.81) | GLP1RNR3C1ECE1MUS81CCKBR | |
| SCHEMBL31087751 | 0.91 | GLP1R (0.91) | GLP1R | |
| SCHEMBL31406268 | 0.91 | GLP1R (0.91) | GLP1R | |
| SCHEMBL31406271 | 0.91 | GLP1R (0.91) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054607-A1 | COMPOSITIONS AND METHODS FOR TREATING SARCOPENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-13 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705296-A1 | HETEROARYLINDOLE INHIBITORS OF APOL-1 | OmniAB, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-106573966-B | Compositions and methods for treating metabolic abnormalities | NGM生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | GLP1R 319/4885NR3C1 785/4885ECE1 4008/4885 |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | FGF1, HDGF, FGF2 | GLP1R 432/4885NR3C1 1782/4885ECE1 1267/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | GLP1R 116/4885NR3C1 274/4885ECE1 1571/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | GLP1R 139/4885NR3C1 266/4885ECE1 3096/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | GLP1R 22/4885NR3C1 143/4885ECE1 713/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | GLP1R 228/4885NR3C1 128/4885ECE1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.